30 closest matches · ranked by relevance
Myeloproliferative Disorders · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants Who Experienced Transplant Related Mortality — 5; 4 Participants
Leukemia · Myeloproliferative Disorders · Myelodysplastic-Myeloproliferative Diseases
Primary: Two-year Overall Survival — 46; 51 percentage of patients
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute · Burkitt Lymphoma
Primary: Overall Survival at 180 Days From the Time of Transplant — 83.7; 62.0 percentage of participants
Hematologic Malignancies · Bone Marrow Transplant Rejection
Primary: The Proportion of Patients Who Develop Full Donor T Cell Chimerism at Day 30 — 44.9 percentage of participants
Sickle Cell Disease
Primary: Percentage of Participants With Overall Survival (OS) at 2 Years After Biologic Assignment — 89; 94 percentage of participants
Acute Lymphocytic Leukemia · Acute Myelogenous Leukemia · Burkitt's Lymphoma
Primary: Percentage of Participants With Progression Free Survival (PFS) — 35.0; 41.1 percentage of participants — p=0.4092
Sickle Cell Disease
Primary: Percentage of Participants With Two-Year Post-Transplant Event Free Survival (EFS) — 88.0; 79.3 Percentage of Participants
Hematologic Neoplasms
Primary: Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for…
Multiple Myeloma
Primary: Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS) — 0.31 Proportion of participants PFS
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute · Burkitt Lymphoma
Primary: Overall Survival at 180 Days From the Time of Transplant — 73.5; 54.0 percentage of participants
Lymphoma, Non-Hodgkin
Primary: Progression-Free Survival (PFS) — 73 percentage of participants
Diamond-Blackfan Anemia · Kostmann's Neutropenia · Shwachman-Diamond Syndrome
Primary: Number of Patients Alive (Survival) at 2 Years — 6 Participants
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Percentage of Participants Who Develop Acute Graft-versus-host Disease (GVHD) — 49; 10 Participants
Lymphoma · HIV
Primary: Overall Survival (OS) — 87.3; 82 percentage of participants
Acute Myeloid Leukemia · Lymphoblastic Leukemia · Acute Leukemia
Primary: Number of Participants With Grade 4 TMI Toxicity — 0; 0; 0; 2 Participants
CML (Chronic Myelogenous Leukemia) · CLL (Chronic Lymphocytic Leukemia) · AML (Acute Myelogenous Leukemia)
Primary: To Determine if Selective T Cell Depletion Using the Photodepletion Procedure Can Substantially Reduce the Rate of Severe Acute GVHD (Grade III/IV) After Matched Sibling…
B-Cell Prolymphocytic Leukemia · Hypodiploidy · Loss of Chromosome 17p
Primary: Event-Free Survival (EFS) — 9 Participants
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Chronic Lymphocytic Leukemia
Primary: Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System — 43; 4 participants
Acute Leukaemia · Chronic Disease · Leukemia
Primary: Number of High Risk Pediatric Patients With Successful Sustained Donor Engraftments — 16; 18; 10 participants
Leukemia, Acute Lymphocytic (ALL) · Leukemia, Myeloid, Acute(AML) · Leukemia, Myeloid, Chronic(CML)
Primary: Event-free Survival (EFS) — 54.8 Percentage of participants
Sickle Cell Disease
Primary: Percentage of Participants With Event-Free Survival (EFS) — 76; 69 percentage of participants
Sickle Cell Disease
Primary: Event -Free Survival Rate — 19 Participants
Hematologic Diseases · Hematologic Malignancies
Primary: Numbers of Participants With Disease-free Survival. — 10 participants
Myelodysplastic Syndrome · Hodgkin's Lymphoma · Non-Hodgkin's Disease
Primary: Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD) — 42; 38 percentage of participants
Accelerated Phase Chronic Myelogenous Leukemia · Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Lymphoblastic Leukemia in Remission
Primary: Day 100 TRM — 8.44 percentage of participants
Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Primary: Overall Survival (OS) in Patients With Haploidentical Family Donors With Hematological Malignancies in Morphological or Radiographic Remission or With Chemosensitive…
Multiple Myeloma
Primary: Progression-Free Survival (PFS) — 46; 43; 33; 40 percentage of patients
Hodgkin's Disease
Primary: Transplant Related Mortality Rate — 1; 6 Participants
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Three-year Relapse-free Survival (RFS) Rate at the Maximum Tolerated Dose Identified During Phase I of the Trial (Target AUC 6912) — 22; 39; 43 percentage of participants
MDS · Leukemias · Lymphomas
Primary: Engraftment as Measured by Donor Chimerism — 91 percentage of participants